Roche to Cut Costs, Review Business After Drug Setbacks; No Details on Size of Cost Reductions or the Number of Staff, Units Affected, Detailed Steps Will be Announced Late 2010

ZURICH/BASEL, Sept 3 (Reuters) - Swiss drugmaker Roche Holding AG (ROG.VX) will review its business and cut costs to cope with recent setbacks on key drugs and rising pressures on prices from healthcare reforms, it said on Friday.